City
Epaper

India likely to have COVID vaccine for children above 2 years by September-October: AIIMS Director

By ANI | Updated: June 23, 2021 21:55 IST

Noting that children usually have a mild disease but there is a need to develop COVID-19 vaccines for them, AIIMS Delhi Director Dr Randeep Guleria has said Bharat Biotech and other companies are doing trials at a very fast pace and hoped that data will lead to approvals so that there is a vaccine for children in the country by September-October.

Open in App

Noting that children usually have a mild disease but there is a need to develop COVID-19 vaccines for them, AIIMS Delhi Director Dr Randeep Guleria has said Bharat Biotech and other companies are doing trials at a very fast pace and hoped that data will lead to approvals so that there is a vaccine for children in the country by September-October.

In an interview with ANI, Dr Guleria said that Covaxin's data for children after completion of phase two or three trials is expected by September-October.

Covaxin is an indigenous vaccine developed by Bharat Biotech in collaboration with ICMR.

"Children usually have the mild disease but we need to develop vaccines for children because if we have to control this pandemic everyone should be vaccinated. Bharat Biotech and other companies are doing trials at a very fast pace as parents have come forward with their children for the trials," he said.

"One is hopeful that trial will be completed early and possibly with follow up of about two-three months, we shall have data by September. Hopefully, by that time, approvals will be there so that by September-October, we'll have vaccines from our country which we can give to children," he added.

Dr Guleria said Bharat Biotech is conducting trials between the age group of 2 to 18 years and "this covers a wide spectrum".

Asked about Zydus Cadila vaccine, he said it is a DNA vaccine, a new platform is being used and "it is something that we should proud of".

He added that it is a platform for which research has not been done in past in the country.

"The data is still being collated and one is hoping that they will be able to submit the data to the DCGI for regulatory approval. It will depend on the company how quickly it is able to collate the data and give it to the regulatory authority," he said.

Asked about Pfizer CEO stating that the company is in the "final stages" of getting approval for its COVID-19 vaccine in India, Dr Guleria said that the firm has been in negotiations for some time and these would have possibly reached the final stage.

"One is hopeful that it should occur because the negotiations with the company is going on for quite some time. I am sure now they are reaching a stage where final sort understanding will be there," he said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Bharat Biotech InternationaldelhiindiaIcmr`delhiDelhi capitalSouth delhi district administrationIndiUk-indiaIto delhi
Open in App

Related Stories

HealthUS Rice Contains Highest Arsenic Levels; Indian Basmati and Thai Jasmine Among Safest, Reveals New Study

NationalAir India Delhi to Washington Flight AI-103 Cancelled Midway in Vienna Due to Technical Snag

NationalCOVID Vaccine Has No Connection With Surge in Sudden Deaths Among Adults; Says ICMR Delhi and AIIMS Study

NationalGold Rate on July 2: Prices in India Rise After 2-Day Dip; Check City-Wise 18K, 22K, and 24K Rates Here

MumbaiMazagaon Murder Case: Accused Zaid Hussain Khan Arrested from Delhi After Month-Long Hunt

National Realted Stories

NationalBodies of couple found hanging from tree in Jharkhand’s Giridih, police suspect love affair

NationalED arrests Delhi-based forex supplier in case linked to Rs 903 crore Chinese App fraud

NationalTata Steel gets Rs 1,902 crore demand notice from Odisha govt

NationalK'taka BJP worker murder case: NIA arrests absconder on arrival from Qatar

NationalJane Street can't get away in India thanks to SEBI: Nithin Kamath